Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

  • Zugasti, Inés
  • Tormo-Ratera, Marta
  • Oliver-Caldés, Aina
  • Soler-Perromat, Juan Carlos
  • González-Calle, Verónica
  • Moreno, David F.
  • Cabañas, Valentín
  • López-Muñoz, Nieves
  • Bartolomé-Solanas, Álvaro
  • Español-Rego, Marta
  • Reguera-Ortega, Juan Luis
  • Rosiñol, Laura
  • López-Corral, Lucía
  • Tovar, Natalia
  • Rodríguez-Lobato, Luis Gerardo
  • Álvarez-Pérez, Rosa María
  • Varea, Sara
  • Olesti, Eulalia
  • Gómez-Grande, Adolfo
  • Frutos, Laura
  • Tamayo, Pilar
  • Juan, Manel
  • Moraleda, José María
  • Urbano-Ispizúa, Álvaro
  • González-Navarro, Azucena
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Tomás, Xavier
  • Setoain, Xavier
  • Fernández de Larrea, Carlos
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. This study included 63 patients with relapsed/refractory MM treated either in the CARTBCMA-HCB-01 clinical trial (ARI0002h; academic B-cell maturation antigen [BCMA]-targeted CAR T-cell therapy) or in compassionate use. The aim was to evaluate the impact of soft-tissue involvement (extramedullary [EMD] and paraskeletal [PS] plasmacytomas) in response, survival and safety. Baseline [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) from 5 participating centers were reviewed centrally. Of 63 patients, 52.4% presented plasmacytomas at the time of inclusion (21 PS, exclusively; and 12 EMD). Per responses, there were no significant differences between patients with and without plasmacytomas. A correlation was present between International Myeloma Working Group responses and those obtained by [18F]FDG-PET/CT at day 100 (Bologna criteria). No differences were observed in progression-free survival (PFS) or overall survival (OS) between patients with or without plasmacytomas. However, both PFS and OS were significantly shorter in patients with EMD. Interestingly, [18F]FDG-PET/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of ≥25 cm3 at baseline [18F]FDG-PET/CT was associated with earlier disease progression and shorter OS. These results highlight the importance of EMD evaluation by [18F]FDG-PET/CT before and after CAR T-cell infusion. This trial was registered at www.ClinicalTrials.gov as #NCT04309981; and EudraCT, 2019-001472-11., This study was supported by grants from the Instituto de Salud Carlos III (cofounded by the European Union) and the Spanish Ministry of Health (ICI19/00025 and PI22/00647), the RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019, RD21/0017/0001, RD21/0017/0006 and RD21/0017/0030), Red de Terapia Celular TERCEL (RD16/0011/0005), Fondo Europeo de Desarrollo Regional, 2021-SGR-01292 (AGAUR; Generalitat de Catalunya), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), La Caixa Foundation (CP042702/LCF/PR/GN18/50310007), Asociación Española Contra el Cancer LABAE21971FERN, and Fundació Bosch I Aymerich support. A.O.-C. from the resident grant Ajut Clínic-La Pedrera 2019, granted by Hospital Clínic de Barcelona. L.G.R.-L. has received funding from the CRIS Cancer Foundation (project number: PR_TMT_2023-6)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

  • Garreta, Elena|||0000-0002-1071-9794
  • Prado, Patricia|||0000-0003-2225-9948
  • Stanifer, Megan|||0000-0002-5606-1297
  • Monteil, Vanessa|||0000-0002-2652-5695
  • Marco Giménez, Andrés|||0000-0002-9831-8433
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Moya Rull, Daniel|||0000-0002-3555-6477
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Tarantino, Carolina|||0000-0003-2470-3803
  • Romero, Juan Pablo|||0000-0002-0441-4791
  • Jonsson, Gustav|||0000-0001-6692-8395
  • Oria, Roger
  • Leopoldi, Alexandra
  • Hagelkruys, Astrid
  • Gallo, Maria|||0000-0001-9099-7235
  • González Grassi, Federico|||0000-0002-7147-2246
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Gavaldà i Navarro, Aleix|||0000-0001-8421-3174
  • Hurtado del Pozo, Carmen
  • Hasan Ali, Omar|||0000-0001-5185-7520
  • Ventura-Aguiar, Pedro|||0000-0003-3381-7503
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Prosper, Felipe|||0000-0001-6115-8790
  • Mirazimi, Ali|||0000-0003-2371-6055
  • Boulant, Steeve|||0000-0001-8614-4993
  • Penninger, Josef|||0000-0002-8194-3777
  • Montserrat, Nuria
It is not well understood why diabetic individuals are more prone to develop severe COVID-19. To this, we here established a human kidney organoid model promoting early hallmarks of diabetic kidney disease development. Upon SARS-CoV-2 infection, diabetic-like kidney organoids exhibited higher viral loads compared with their control counterparts. Genetic deletion of the angiotensin-converting enzyme 2 (ACE2) in kidney organoids under control or diabetic-like conditions prevented viral detection. Moreover, cells isolated from kidney biopsies from diabetic patients exhibited altered mitochondrial respiration and enhanced glycolysis, resulting in higher SARS-CoV-2 infections compared with non-diabetic cells. Conversely, the exposure of patient cells to dichloroacetate (DCA), an inhibitor of aerobic glycolysis, resulted in reduced SARS-CoV-2 infections. Our results provide insights into the identification of diabetic-induced metabolic programming in the kidney as a critical event increasing SARS-CoV-2 infection susceptibility, opening the door to the identification of new interventions in COVID-19 pathogenesis targeting energy metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

  • Lasaga, Miren
  • Río, Paula
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Planell, Núria
  • Navarro, Susana|||0000-0002-6753-546X
  • Alignani, Diego
  • Fernández-Varas, Beatriz
  • Mouzo, Daniel
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Nicoletti, Eileen
  • Schwartz, Jonathan D.
  • Sevilla, Julián|||0000-0002-6852-1860
  • Ainciburi, Marina
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Surralles, Jordi|||0000-0002-4041-7519
  • Perona, Rosario|||0000-0002-2973-5153
  • Sastre, Leandro|||0000-0003-3613-5938
  • Prosper, Felipe|||0000-0001-6115-8790
  • Gomez-Cabrero, David
  • Bueren, Juan|||0000-0002-3228-7013
Clinical trials have shown that lentiviral-mediated gene therapy can ameliorate bone marrow failure (BMF) in non-conditioned Fanconi anemia (FA) patients resulting from the proliferative advantage of corrected FA hematopoietic stem and progenitor cells (HSPC). However, it is not yet known if gene therapy can revert affected molecular pathways in diseased HSPC. Single-cell RNA sequencing was performed in chimeric populations of corrected and uncorrected HSPC co-existing in the BM of gene therapy-treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC. This includes a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways. Our results show for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional program from patients with inherited diseases; in this case, in FA characterized by BMF and cancer predisposition.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction

  • Garbayo, Elisa
  • Ruiz-Villalba, Adrián
  • Hernández, Silvia C.
  • Saludas, Laura
  • Abizanda, Gloria
  • Pelacho, Beatriz
  • Roncal Mancho, Carmen
  • Sánchez, B. (Belén)
  • Palacios, Itziar
  • Prósper, Felipe
  • Blanco-Prieto, María J.
Despite tremendous progress in cell-based therapies for heart repair, many challenges still exist. To enhance the therapeutic potential of cell therapy one approach is the combination of cells with biomaterial delivery vehicles. Here, we developed a biomimetic and biodegradable micro-platform based on polymeric microparticles (MPs) capable of maximizing the therapeutic potential of cardiac progenitor cells (CPCs) and explored its efficacy in a rat model of chronic myocardial infarction. The transplantation of CPCs adhered to MPs within the infarcted myocardial microenvironment improved the long-term engraftment of transplanted cells for up to one month. Furthermore, the enhancement of cardiac cellular retention correlated with an increase in functional recovery. In consonance, better tissue remodeling and vasculogenesis were observed in the animals treated with cells attached to MPs, which presented smaller infarct size, thicker right ventricular free wall, fewer deposition of periostin and greater density of vessels than animals treated with CPCs alone. Finally, we were able to show that part of this beneficial effect was mediated by CPC-derived extracellular vesicles (EVs). Taken together, these findings indicate that the biomimetic microcarriers support stem cell survival and increase cardiac function in chronic myocardial infarction through modulation of cardiac remodeling, vasculogenesis and CPCs-EVs mediated therapeutic effects. The biomimetic microcarriers provide a solution for biomaterial-assisted CPC delivery to the heart., This work was supported by the FEDER/Ministry of Science and Innovation-State Research Agency/SAF2017-83734-R and funds from the ISCIII and co-financed by FEDER (PI19/00501), Red TERCEL RETIC RD16/0011/0005 and MINECO (Program RETOS Cardiomesh RTC-2016-4911-1), ERANET II (Nanoreheart AC15/00050), and EU's H2020 Programme for research, technological development and demonstration under grant agreement BRAV¿-874827. Elisa Garbayo is supported by a FSE/Ministry of Science and Innovation-State Research Agency RYC2018-025897-I. Adrian Ruiz-Villalba is supported by the Spanish Ministry of Sciences and Innovations FSE/MINECO-AEI(IJCI-2016-30254), and the Spanish Ministerio de Ciencia, Innovación y Universidades (grant RTI2018-095410-BI00). We thank Filippo Roli and Elena Iglesias for technical support.